The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa

Anorexia Nervosa Clinical Trial

Official title:

Investigating the Impact of Oxytocin on the Neurobiological Underpinnings of Socioemotional Deficits in Anorexia Nervosa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03414112
• Other study ID #: PSYCH-2017-26002
• Status: Completed
• Phase: Early Phase 1
• Start date: September 25, 2018
• Est. completion date: April 30, 2021

Study information

• Verified date: February 2022
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will use a randomized, controlled, double-blind design involving the administration of intranasal oxytocin (INOT) or placebo to adults with anorexia nervosa, restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli as well as eating behavior in a test meal paradigm.

Description:

The primary objective of this investigation is to determine the impact of oxytocin (OT), a peptide hormone that influences social affiliation, on socioemotional neural circuitry and eating disorder behavior in anorexia nervosa (AN). Because socioemotional processing deficits appear to play a key role in AN, OT is implicated as a potential biological mechanism by which eating disorder behavior (e.g., restrictive eating) is maintained. Used as a probe, intranasal oxytocin (INOT) provides an innovative method for examining the short-term impact of OT on socioemotional neural processing disturbances and eating disorder behavior in AN. The proposed study tests a theoretical model of the role of OT in the maintenance of AN by using an INOT probe to determine, and potentially alter, neurobiological responses to socioemotional stimuli. Specifically, this study will use a randomized, controlled, double-blind design involving the administration of INOT or placebo to adults with AN restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli. The potential impact of INOT on restrictive eating will also be assessed in a subsequent test meal. We predict that for participants with AN, INOT, but not placebo, will normalize frontolimbic activation in response to social reward stimuli and prefrontal activation in response to social threat stimuli. In addition, the investigators predict that AN participants will display reduced restrictive eating in a test meal paradigm following INOT (but not placebo) administration. Finally, investigators predict that changes in restrictive eating following INOT administration will be mediated by altered frontolimbic responding to socioemotional cues. This investigation will provide an essential link uniting the data supporting the importance of socioemotional processing deficits in AN with the emerging role of INOT in altering the neural circuits involved in social behavior to test an innovative neurobiological maintenance model of AN.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: April 30, 2021
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All participants:

1. Age > 18 years old

2. Female (given the potential sex differences to endogenous OT to INOT)

3. Ability to read and speak in English

4. Right-handed

• Anorexia nervosa participants:

1. DSM-5 diagnosis of AN, restricting subtype (established by the SCID-5-RV),

2. BMI < 18.5 kg/m2 within the past month

Exclusion Criteria:

All participants

1. Medical instability or current pregnancy or lactation

2. Current substance use disorder, psychosis, or bipolar-I disorder

3. Contraindication for fMRI (e.g., implanted metal)

4. History of neurological disorder/injury (e.g., stroke; head injury with > 10 minutes loss of consciousness)

5. Food allergy that cannot be accommodated through substitutions to the laboratory test meal

6. Lacking capacity to consent

7. Contraindications for intranasal oxytocin administration

8. Acute suicidality

9. Psychoactive medication (e.g., antidepressants, antipsychotics)

Exclusion for participants without anorexia nervosa

1. Current DSM-5 Axis-I diagnosis or current or past eating disorder diagnosis

2. BMI < 19.0

Related Conditions & MeSH terms

• Anorexia
• Anorexia Nervosa

Intervention

Biological:
• Intranasal oxytocin
oxytocin is a peptide hormone that influences social affiliation

Locations

Country	Name	City	State
United States	University of Minnesota - Dept of Psychiatry	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
University of Minnesota	Klarman Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Test meal	Participants will complete a test meal	Following intranasal oxytocin or placebo (within 1-3 hours)
Primary	fMRI measures	Neural activation in regions of interest (ROIs) in socioemotional circuitry (i.e., ACC, amygdala, medial PFC, NAcc) in response to INOT or placebo and social threat vs. neutral tasks and social reward vs. neutral stimuli	Following intranasal oxytocin or placebo administration (within 1-3 hours)